Pilot Study of Eplerenone for Heart Health in Primary Aldosteronism
This study is exploring how the medication eplerenone might improve heart health in people with primary aldosteronism (a condition where your body makes too much of the hormone aldosterone, leading to high blood pressure). Researchers want to see if 6 months of treatment with eplerenone can improve blood flow in your heart. You may be able to join if you are an adult between 18 and 85 years old, have high blood pressure, and have a confirmed diagnosis of primary aldosteronism. The study aims to enroll 40 participants, but its current recruitment status is unclear.
- Study design
- This is an interventional pilot study with no specified phase, planning to enroll 40 participants. It evaluates the effect of eplerenone treatment.
- What's involved
- You would receive eplerenone daily for 6 months. Before and after this treatment, you would have heart imaging tests, including a PET scan and an echocardiogram.
- Compensation
- Not stated in the trial record.
- Follow-up
- Your heart's blood flow will be measured at 6 months, which is the end of the treatment period.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study
At a glance
Conditions
Where it's being run
1 sites across 1 statesWho to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
Exclusion
What this trial measures
- Change in myocardial flow reserve (MFR, unitless ratio)6 months
The primary outcome is to evaluate the change in MFR, as measured by PET, pre- vs post-6 months of eplerenone therapy